Blood tests before starting a GLP-1 or a peptide, and which to repeat
Reviewed 12 sourcesPublished by PepVault
What the FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound, tesamorelin, growth hormone and testosterone test before the first dose and which they repeat.

- Last reviewed
- Sources
- 12
- Questions
- 8
- Compounds
- 7
The short answer
The GLP-1 labels set no blood test for everyone before the first dose. With diabetes, Wegovy's and Zepbound's labels check blood glucose before and during treatment, and all four ask for a kidney check when nausea, vomiting or diarrhea could dry you out. Tesamorelin checks glucose first, then IGF-1. Testosterone labels confirm two low morning results, then recheck hematocrit. Your prescriber sets the panel.
- No GLP-1 label requires a baseline blood panel for everyone; glucose is checked before and during treatment in people with diabetes.
- The thyroid warning is a question about your history, not a calcitonin test: the labels call routine calcitonin of uncertain value.
- Anything that raises growth hormone raises IGF-1 and can raise glucose, so those are the two markers its labels and studies follow.
- Testosterone labels follow hematocrit; Xyosted's also follows PSA and lipids and checks hematocrit about every 3 months.
Evidence: Strong for the approved drugs: these are the FDA labels' own monitoring lines. For unapproved research peptides, only small human studies (2 to 65 people) that measured blood markers, not a testing rule.

Do you need blood work before starting a GLP-1?
Not by the labels, for most people. The FDA labels for Ozempic, Wegovy, Mounjaro and Zepbound list no blood test that everyone must have before the first dose1234. A label is the drug's official prescribing information, and its monitoring lines are written for the situations where a result changes what the prescriber does. The table puts those situations side by side.
| Test | What the labels say | Which labels |
|---|---|---|
| Blood glucose | With diabetes, check it before starting and during treatment. Taken with insulin or a sulfonylurea, low blood sugar is more likely and those doses may need lowering. | Wegovy and Zepbound (before and during); all four (the insulin line)1234 |
| Kidney function (creatinine, eGFR) | Check it in anyone whose nausea, vomiting or diarrhea could dry them out, especially while the dose is started and raised. | All four1234 |
| Calcitonin, a thyroid hormone | Routine testing is of uncertain value. A raised result gets a further look. | All four1234 |
| Lipase and amylase, two pancreas enzymes | Not a required test. The trials saw average rises in both. | All four1234 |
| Eye exam (not a blood test) | With a history of diabetic retinopathy, watch for it worsening: a fast improvement in blood sugar control has been linked to a temporary worsening. | All four1234 |
So the tests a GLP-1 label cares about are the ones that catch its known effects: low blood sugar when it is stacked on other diabetes drugs, kidneys strained by fluid loss, and the eyes of people who already have diabetic eye disease. A kidney or glucose result from before the first dose gives a later one something to be compared with.
Commonly reported: a lower fasting glucose and HbA1c at the first recheck, and a lab portal flagging a high lipase in someone who feels fine.
PepVault's bloodwork section reads a lab report from a photo or a PDF, or takes it by hand, and draws each marker's trend from one panel to the next. Log it in PepVault

What does the thyroid warning mean for blood tests?
Every GLP-1 label carries a boxed warning, the FDA's strongest kind, about thyroid C-cell tumors seen in rodents; whether the drugs cause them in people is unknown1234. The labels turn that into a question about your history rather than a blood test: the drugs are not for anyone with a personal or family history of medullary thyroid cancer (MTC) or with MEN 2, an inherited syndrome that causes it1234.
Calcitonin is the hormone those C-cells make. The labels say routine calcitonin testing or thyroid ultrasound is of uncertain value for catching MTC early, and that it can lead to procedures nobody needed, because the test is not specific and thyroid disease is common anyway1234. If a calcitonin is measured and comes back raised, the label asks for a further look; people with MTC usually have levels over 50 ng/L1234.
Why might lipase read high on a GLP-1?
Lipase and amylase are enzymes made by the pancreas, and a high level can be a sign of pancreatitis, an inflamed pancreas. In the trials, though, both rose on average in people taking the drugs, while placebo moved them little or not at all1234. These are the labels' own averages:
| Drug | Average lipase rise | Average amylase rise |
|---|---|---|
| Ozempic | 22%1 | 13%1 |
| Wegovy (weight trials) | 39%2 | 15 to 16%2 |
| Mounjaro | 31 to 42%3 | 33 to 38%3 |
| Zepbound (placebo: 5.8% and 2.1%) | 28 to 35%4 | 20 to 25%4 |
Wegovy's, Mounjaro's and Zepbound's labels say what those rises mean in the absence of other signs of pancreatitis is unknown234. So a lipase that has risen on a GLP-1 matches what the trials saw on average; the symptoms are what the labels ask people to watch.
When to get help Stomach pain that is severe or will not go away, sometimes reaching through to the back, with or without vomiting, is the labels' sign of pancreatitis and a reason to get medical help promptly1234.
Which tests do tesamorelin and growth hormone labels ask for?
Growth hormone (somatropin) and tesamorelin, which makes the pituitary release more of its own growth hormone, share two effects that shape their tests. They raise IGF-1, the growth factor the liver makes in answer to growth hormone, and they can push blood sugar up57. Tesamorelin is FDA-approved as Egrifta to reduce excess belly fat in adults with HIV and lipodystrophy; somatropin's labels, Genotropin's here, cover growth hormone deficiency and other growth disorders.
| Test | Tesamorelin (Egrifta SV, Egrifta WR) | Somatropin (Genotropin) |
|---|---|---|
| Glucose | Evaluate before starting, then check periodically for impaired glucose tolerance or diabetes56 | Check periodically in everyone, closely with diabetes or impaired glucose tolerance7 |
| IGF-1 | Monitor during treatment; consider stopping if it stays high (for example over 3 SDS), especially if the belly fat has not gone down much56 | Guides the adult dose: lower it if IGF-1 runs above the range for age and sex7 |
| Thyroid function | No line | Periodic tests: low thyroid can first appear or worsen on treatment7 |
| Cortisol | No line | Watch for low cortisol in people with, or at risk of, other pituitary hormone gaps7 |
| Eye exam (not a blood test) | With diabetes, at regular intervals for retinopathy56 | Before starting and periodically, for swelling at the back of the eye7 |
SDS is how far a result sits from the average for your age, counted in standard deviations. In the tesamorelin trials, 47% of people had an IGF-1 above 2 SDS after 26 weeks and 36% above 3, seen as early as week 135. Somatropin's label adds that phosphorus, alkaline phosphatase and parathyroid hormone may rise on treatment, so a change there can be the drug itself7.
What do testosterone labels ask you to test?
The first check comes before any shot: the labels confirm low testosterone with morning blood tests on at least two separate days, both below the normal range89. The checks that follow are about red blood cells, the prostate and blood fats. The guide to raising testosterone covers the diagnosis and the options; this table covers the follow-up.
| Test | Before starting | Then |
|---|---|---|
| Total testosterone, in the morning | Two low results on separate days89 | Xyosted: a trough level, 7 days after a dose, at 6 weeks, 6 weeks after any dose change, and periodically8 |
| Hematocrit, the share of blood that is red cells | Xyosted: check it is not already raised8 | Xyosted: about every 3 months8. Depo-Testosterone: hemoglobin and hematocrit periodically on long-term use9 |
| PSA (prostate-specific antigen) | Evaluate for prostate cancer8 | Periodically8 |
| Lipid profile | No line | Periodically, particularly after starting8 |
The reason hematocrit leads the list: in Xyosted's one-year study of 150 men, a rising hematocrit was the most common side effect, in 14%, and a rising PSA came in 12%8. A raised hematocrit means a pause on the label: Xyosted is stopped until the level comes down, and stopped for good if it rises again after a restart8.
What did studies of research peptides measure?
Research peptides such as BPC-157 and CJC-1295, and the pill MK-677, have no FDA label, so no label says what to test. What exists are human studies that measured blood markers. These are study results, not a testing rule.
| Compound | The study | What it measured | What changed |
|---|---|---|---|
| MK-677 (oral) | 2 years, 65 healthy adults aged 60 to 81, against placebo10 | Growth hormone, IGF-1, fasting glucose, insulin sensitivity, lipids, cortisol | IGF-1 rose to young-adult levels; fasting glucose up 5 mg/dL on average; insulin sensitivity fell; LDL down 5.4 mg/dL from baseline; cortisol up 1.7 mcg/dL10 |
| CJC-1295 (the DAC form) | Two placebo-controlled trials of 28 and 49 days, healthy adults aged 21 to 6111 | Growth hormone and IGF-1 | One shot raised growth hormone 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days11 |
| BPC-157 (into a vein) | A pilot in 2 people over 3 days12 | Heart, liver, kidney and thyroid markers, blood glucose | No measurable change12 |
The pattern matches the approved drugs that act on the same system: what raises growth hormone raised IGF-1, and in the longest study it nudged glucose up. That is why IGF-1 and glucose are the markers these studies kept coming back to. The BPC-157 pilot is two people, so it shows what was tested rather than settling safety; the guide to BPC-157's human data covers the rest.
Which tests do the labels say to repeat?
| Family | Before the first dose | Repeat |
|---|---|---|
| GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) | Nothing for everyone; glucose with diabetes (Wegovy, Zepbound) | Glucose during treatment with diabetes; kidney function if side effects could dehydrate; eye checks with diabetic retinopathy |
| Tesamorelin | Glucose | IGF-1 during treatment; glucose periodically |
| Somatropin | Eye exam | Glucose, thyroid function and IGF-1, periodically |
| Testosterone | Two low morning results; hematocrit and a prostate check (Xyosted) | Hematocrit about every 3 months (Xyosted); PSA and lipids periodically; a testosterone trough at 6 weeks (Xyosted) |
| Research peptides | No label | No label; the studies of growth hormone raisers followed IGF-1 and glucose |
"Periodically" is the labels' own word: they leave the interval to the prescriber, and which tests a person gets, and when, is the prescriber's call.
Markers PepVault doesn't list, such as calcitonin, lipase or PSA, go in as custom markers with their own unit and range, so every test in these tables can sit in one place. Log it in PepVault
How do you make the next panel comparable with the first?
- Keep a copy of every result with its units and the lab's reference range, since ranges differ from lab to lab.
- Use the same lab when you can, so the method stays the same.
- Have blood drawn at the same time of day; the testosterone labels specify morning, and Xyosted's trough is drawn 7 days after a dose8.
- Note the date of your first dose, so each panel sits clearly before or after it.
- Log each panel the day the result arrives.
With two or more panels from 30 days before your protocol's start onward, PepVault's doctor's report sets them side by side with the change in each marker. Log it in PepVault
Sources
- Ozempic (semaglutide) injection. Prescribing information, Novo Nordisk, June 2026. DailyMed. dailymed.nlm.nih.gov
- Wegovy (semaglutide) injection and tablets. Prescribing information, Novo Nordisk, June 2026. DailyMed. dailymed.nlm.nih.gov
- Mounjaro (tirzepatide). Prescribing information, Eli Lilly, August 2026. DailyMed. dailymed.nlm.nih.gov
- Zepbound (tirzepatide). Prescribing information, Eli Lilly, August 2026. DailyMed. dailymed.nlm.nih.gov
- Egrifta WR (tesamorelin). Prescribing information, Theratechnologies, July 2026. DailyMed. dailymed.nlm.nih.gov
- Egrifta SV (tesamorelin). Prescribing information, Theratechnologies, July 2026. DailyMed. dailymed.nlm.nih.gov
- Genotropin (somatropin). Prescribing information, Pfizer, August 2026. DailyMed. dailymed.nlm.nih.gov
- Xyosted (testosterone enanthate) injection. Prescribing information, Antares Pharma, July 2025. DailyMed. dailymed.nlm.nih.gov
- Depo-Testosterone (testosterone cypionate) injection. Prescribing information, Pfizer, November 2026. DailyMed. dailymed.nlm.nih.gov
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PubMed 18981485
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.